Development of Lipid-Engineered PSMA-Targeted Radioligands with Quinoline Scaffold
Lu]Lu-PDA1-1. Overall, this proof-of-concept study validated that conjugating PSMA ligands with tailor-made lipid chain and fatty acids can markedly enhance tumor uptake and retention while maintaining a low level of kidney retention.
Authors
- Zhide Guo (ORCID: https://orcid.org/0000-0002-9110-159X)
- Jianyang Fang (ORCID: https://orcid.org/0009-0008-1722-6088)
- Xianzhong Zhang (ORCID: https://orcid.org/0000-0001-8591-8301)
- Y L Li
- Yaoxuan Wang
- Zhexin He
- Hongwu Liu (ORCID: https://orcid.org/0000-0002-2218-0757)
- Liwei Hong
- Tao Zhang
Institutions
- Fujian Medical University (CN)
- Xiamen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Zhangzhou Municipal Hospital of Fujian Province (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00257
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fujian Provincial Department of Science and Technology
- Xiamen University
- Fundamental Research Funds for the Central Universities